Approximately 40% of the patients with hormone receptor-positive, HER2-negative breast cancer have activating mutations in PIK3CA, which encodes the catalytic subunit of PI3K, p110α, displaying hyperactivity [8, 9]. Here, PIK3CA is linked to breast carcinoma.